Cargando…

Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma

Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome that involves the production of autoantibodies which can cross-react with retinal epitopes leading to visual symptoms. Autoantibodies can target intracellular proteins, and only a few are directed against membrane proteins. This disc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaddour, Karam, Khanna, Sangeeta, Ansstas, Michael, Jakhar, Ishaan, Dahiya, Sonika, Council, Laurin, Ansstas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360886/ https://www.ncbi.nlm.nih.gov/pubmed/33544215 http://dx.doi.org/10.1007/s00262-021-02875-x

Ejemplares similares

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency
por: Khaddour, Karam, et al.
Publicado: (2021)

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2023)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Khaddour, Karam, et al.
Publicado: (2021)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
por: Khaddour, Karam, et al.
Publicado: (2023)

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
por: Khaddour, Karam, et al.
Publicado: (2020)

Serum TRPM1 Autoantibodies from Melanoma Associated Retinopathy Patients Enter Retinal ON-Bipolar Cells and Attenuate the Electroretinogram in Mice
por: Xiong, Wei-Hong, et al.
Publicado: (2013)

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa
por: Khaddour, Karam, et al.
Publicado: (2020)

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome
por: Khaddour, Karam, et al.
Publicado: (2019)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
por: Shmuylovich, Leonid, et al.
Publicado: (2022)

Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3
por: Duvoisin, Robert M., et al.
Publicado: (2017)

Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy
por: Varin, Juliette, et al.
Publicado: (2020)

Correction: Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy
Publicado: (2020)

Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis
por: Jaeger, Zachary J., et al.
Publicado: (2023)

Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
por: Hwang, Helen, et al.
Publicado: (2022)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
por: Ansstas, George, et al.
Publicado: (2016)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Electroretinogram Changes Following Sequential Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
por: Khojasteh, Hassan, et al.
Publicado: (2020)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
por: Du, Fei, et al.
Publicado: (2023)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

BRAF mutations may identify a clinically distinct subset of glioblastoma
por: McNulty, Samantha N., et al.
Publicado: (2021)

TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms
por: Duvoisin, Robert M., et al.
Publicado: (2019)

Full‐field and multifocal electroretinogram in non‐diabetic controls and diabetics with and without retinopathy
por: Ba‐Ali, Shakoor, et al.
Publicado: (2022)

Clinical Findings of Melanoma-Associated Retinopathy with anti-TRPM1 Antibody
por: Shinohara, Yoichiro, et al.
Publicado: (2021)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

A diagnostic autoantibody signature for primary cutaneous melanoma
por: Zaenker, Pauline, et al.
Publicado: (2018)

Neuronal autoantibodies associated with cognitive impairment in melanoma patients
por: Bartels, F, et al.
Publicado: (2019)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

Data analysis of PD-1 antibody in the treatment of melanoma patients
por: Li, Ting, et al.
Publicado: (2020)

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
por: Gellrich, Frank Friedrich, et al.
Publicado: (2020)

Nanometer-scale distribution of PD-1 in the melanoma tumor microenvironment
por: Comerci, Colin J, et al.
Publicado: (2023)

Unilateral Melanoma-Associated Retinopathy Case Report
por: Peeters, Reinout, et al.
Publicado: (2023)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8fm5orohvi38ase3tuj9lf7cq0